Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).

The formation of vasoconstrictors (e.g., angiotensin II and endothelin) and the inactivation of vasodilators (e.g., bradykinin and atrial natriuretic) by membrane-bound zinc metallopeptidases are key mechanisms in the control of blood pressure and fluid homeostasis. The way in which these peptides modulate physiological functions has been intensively studied. With the aim to develop compounds that can jointly block the three metallopeptidases-neutral endopeptidase (NEP, neprilysin), angiotensin-converting enzyme (ACE), and endothelin-converting enzyme (ECE-1)-we studied the common structural specificity of the S1' subsites of these peptidases. Various mercaptoacyl amino acids of the general formula HS-CH2-CH(R1')CO-Trp-OH, possessing more or less constrained R1' side chains, were designed. The mercapto-acyl synthons contain one or two asymmetrical centers. The K(i) values of the separated stereoisomers of the most efficient inhibitors were used to determine the stereochemical preference of each enzyme. A guideline for the joint inhibition of the three peptidases was obtained with the (2R,3R) isomer of compound 13b. Its K(i) values on NEP, ACE, and ECE were 0.7, 43, and 26 nM, respectively.

[1]  B. Roques,et al.  Exploration of the S  ′1 subsite of neprilysin: A joined molecular modeling and site‐directed mutagenesis study , 2000, Proteins.

[2]  Affinity chromatographic purification of angiotensin converting enzyme. , 1984, Biochemistry.

[3]  R. Chang,et al.  (Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists. , 1993, Journal of medicinal chemistry.

[4]  M. Fournié-Zaluski,et al.  Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. , 1993, Pharmacological reviews.

[5]  G. Ksander,et al.  Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme. , 1998, Journal of cardiovascular pharmacology.

[6]  J. Robl,et al.  Recent advances in the design and development of vasopeptidase inhibitors , 1999 .

[7]  C. Oefner,et al.  A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP). , 2001, Protein engineering.

[8]  M. Roth,et al.  Studies on the angiotensin converting enzyme with different substrates. , 1970, Biochimica et biophysica acta.

[9]  B. Roques,et al.  Relationship between the inhibitory potencies of thiorphan and retrothiorphan enantiomers on thermolysin and neutral endopeptidase 24.11 and their interactions with the thermolysin active site by computer modelling. , 1987, Biochemical and biophysical research communications.

[10]  A. Stamford,et al.  DESIGN AND SYNTHESIS OF PHOSPHINIC ACIDS THAT TRIPLY INHIBIT ENDOTHELIN CONVERTING ENZYME, ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE 24. 11 , 1996 .

[11]  A. Romieu,et al.  Highly sensitive and selective fluorescence assays for rapid screening of endothelin-converting enzyme inhibitors. , 2001, The Biochemical journal.

[12]  B. Roques,et al.  1H NMR configurational correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of "enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition. , 1986, Journal of medicinal chemistry.

[13]  J. Dumas,et al.  Thiol inhibitors of endothelin-converting enzyme , 1996 .

[14]  B Rubin,et al.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. , 1977, Science.

[15]  Regine Bohacek,et al.  Three-Dimensional Models of ACE and NEP Inhibitors and Their Use in the Design of Potent Dual ACE/NEP Inhibitors , 1996 .

[16]  B. Roques,et al.  Dns-Gly-(p-NO2)Phe-beta Ala, a specific fluorogenic substrate for neutral endopeptidase 24.11. , 1994, Analytical biochemistry.

[17]  F. Winkler,et al.  Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. , 2000, Journal of molecular biology.

[18]  J. Barrish,et al.  Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitors , 1996 .

[19]  B. Jarvis,et al.  Lisinopril , 2000, Drugs.

[20]  M. Fournié-Zaluski,et al.  New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. , 1994, Journal of medicinal chemistry.

[21]  T. Phan,et al.  Migration du groupe éthoxycarbonyle dans la transposition de Wagner-Meerwein , 1976 .

[22]  J. Schwartz,et al.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice , 1980, Nature.

[23]  David J. Symonsbergen,et al.  Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1. , 2000, Bioorganic & medicinal chemistry letters.

[24]  B. Roques.  Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives. , 1998, Pathologie-biologie.

[25]  J. Ménard,et al.  Angiotensin-converting enzyme inhibitors. , 2001, Advances in protein chemistry.

[26]  E. Golomb,et al.  Role of neutral endopeptidase in the metabolism of endothelin. , 1992, Hypertension.

[27]  B. Roques,et al.  Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives? , 1990, Trends in pharmacological sciences.

[28]  R. Davis,et al.  Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. , 1997, Drugs.